Skip to main content
Journal cover image

Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555.

Publication ,  Journal Article
Levin, ED; McGurk, SR; Rose, JE; Butcher, LL
Published in: Pharmacol Biochem Behav
August 1989

Pharmacological blockade of either nicotinic or muscarinic cholinergic receptors has been found to impair choice accuracy in the radial-arm maze. Simultaneous blockade of both of these receptor types causes an additive impairment. However, despite these common effects, nicotinic and muscarinic receptors have been found to have differential involvement with dopamine receptors. The cognitive impairment caused by the muscarinic antagonist scopolamine is reversed by the D1 antagonist SCH 23390 but is unaffected by the D2 antagonist raclopride. In contrast, the cognitive impairment caused by the nicotinic antagonist mecamylamine is unaffected by SCH 23390 but is potentiated by raclopride. In the current study, the D2 agonist LY 171555 was found to be effective in reversing the radial-arm maze choice accuracy impairment caused by mecamylamine. In contrast, the D1 agonist SKF 38393 was not found to be effective. Thus, we have found selective dopaminergic D1 and D2 treatments which counteract the adverse cognitive effects of either nicotinic or muscarinic blockade. A combination of these treatments may be useful in treating the cognitive effects of generalized cholinergic underactivation.

Duke Scholars

Published In

Pharmacol Biochem Behav

DOI

ISSN

0091-3057

Publication Date

August 1989

Volume

33

Issue

4

Start / End Page

919 / 922

Location

United States

Related Subject Headings

  • Receptors, Dopamine
  • Rats, Inbred Strains
  • Rats
  • Quinpirole
  • Neurology & Neurosurgery
  • Mecamylamine
  • Female
  • Ergolines
  • Drug Interactions
  • Dopamine Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Levin, E. D., McGurk, S. R., Rose, J. E., & Butcher, L. L. (1989). Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555. Pharmacol Biochem Behav, 33(4), 919–922. https://doi.org/10.1016/0091-3057(89)90494-2
Levin, E. D., S. R. McGurk, J. E. Rose, and L. L. Butcher. “Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555.Pharmacol Biochem Behav 33, no. 4 (August 1989): 919–22. https://doi.org/10.1016/0091-3057(89)90494-2.
Levin ED, McGurk SR, Rose JE, Butcher LL. Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555. Pharmacol Biochem Behav. 1989 Aug;33(4):919–22.
Levin, E. D., et al. “Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555.Pharmacol Biochem Behav, vol. 33, no. 4, Aug. 1989, pp. 919–22. Pubmed, doi:10.1016/0091-3057(89)90494-2.
Levin ED, McGurk SR, Rose JE, Butcher LL. Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555. Pharmacol Biochem Behav. 1989 Aug;33(4):919–922.
Journal cover image

Published In

Pharmacol Biochem Behav

DOI

ISSN

0091-3057

Publication Date

August 1989

Volume

33

Issue

4

Start / End Page

919 / 922

Location

United States

Related Subject Headings

  • Receptors, Dopamine
  • Rats, Inbred Strains
  • Rats
  • Quinpirole
  • Neurology & Neurosurgery
  • Mecamylamine
  • Female
  • Ergolines
  • Drug Interactions
  • Dopamine Agents